The use of intravenous iron in patients with cancer-related anaemia

British Journal of Haematology

Volumn 141, Issue 6, 2008, Pages 751-756

  Littlewood, T J ^a,b   Alikhan, R ^a  

^a OXFORD UNIVERSITY HOSPITALS NHS FOUNDATION TRUST   (United Kingdom)

^b JOHN RADCLIFFE HOSPITAL   (United Kingdom)

Author keywords

Cancer anaemia; Erythropoiesis stimulating agents; Intravenous iron

Indexed keywords

COSMOFER; DEFEROXAMINE; DEXFERRUM R; DEXTRAN; ERYTHROPOIETIN; FERINJECT R; FERRIC GLUCONATE; FERRIC HYDROXIDE SUCROSE; FERROUS SULFATE; HEMOGLOBIN; IRON; IRON DEXTRAN; NOVEL ERYTHROPOIESIS STIMULATING PROTEIN; PLACEBO; RECOMBINANT ERYTHROPOIETIN;

ANAPHYLAXIS; ANEMIA; ARTHRALGIA; BACKACHE; CHRONIC DISEASE; CHRONIC KIDNEY FAILURE; CLINICAL TRIAL; DRUG EFFICACY; DRUG SAFETY; HUMAN; HYPERSENSITIVITY; HYPOTENSION; INFECTION; IRON THERAPY; MEDICAL LITERATURE; MYALGIA; NAUSEA; NEOPLASM; PRIORITY JOURNAL; REVIEW; THROMBOPHLEBITIS; UNSPECIFIED SIDE EFFECT;

ANEMIA, IRON-DEFICIENCY; CHEMISTRY, PHARMACEUTICAL; CHRONIC DISEASE; HUMANS; INFUSIONS, INTRAVENOUS; IRON; KIDNEY FAILURE, CHRONIC; NEOPLASMS;

EID: 44249107891     PISSN: 00071048     EISSN: 13652141     Source Type: Journal    
DOI: 10.1111/j.1365-2141.2008.07118.x     Document Type: Review

References (39)

1. Auerbach, M. (2007) Intravenous iron. New England Journal of Medicine, 357, 93 94.
2. Auerbach, M., Ballard, H., Trout, J.R., Mcilwain, M., Ackerman, A., Bahrain, H., Balan, S., Barker, L. Rana, J. (2004) Intravenous iron optimizes the response to recombinant human erythropoietin in cancer patients with chemotherapy-related anemia: a multi-center, open-label, randomized trial. Journal of Clinical Oncology, 22, 1301 1307.
3. Bellet, R.E., Ghazal, H., Flam, M., Drelichman, A., Gabrail, D., Woytowitz, D., Loesch, D., Niforos, A., Mangione, L. Anthonyf or the Iron Sucrose Study Group (2007) A phase III randomized, controlled study comparing iron sucrose intravenously (IV) to no iron treatment of anaemia in cancer patients undergoing chemotherapy and erythropoietin stimulating agent (ESA) therapy. Journal of Clinical Oncology, ASCO Annual Meeting Proceedings Part I. Vol 25, No. 18S (June 20 Supplement), 9109.
4. Bennett, C.L., Cournoyer, D., Carson, K.R., Rossert, J., Luminari, S., Evens, A.M., Locatelli, F., Belknap, S.M., Mckoy, J.M., Lyons, E.A., Kim, B., Sharma, R., Costello, S., Toffelmire, E.B., Wells, G.A., Messner, H.A., Yarnold, P.R., Trifilio, S.M., Raisch, D.W., Kuzel, T.M., Nissenson, A., Lim, L.C., Tallman, M.S. Casadevall, N. (2005) Long term outcome of individuals with pure red cell aplasia and antierythropoietin antibodies in patients treated with recombinant erythropoietin: a follow-up report from the research on adverse drug events and reports (RADAR). Blood, 106, 3343 3347.
5. Bokemeyer, C., Aapro, M.S., Courdi, A., Foubert, J., Link, H., Osterborg, A., Repetto, L. Soubeyran, P. (2007) EORTC guidelines for the use of erythropoietic proteins in anaemic patients with cancer: 2006 update. European Journal of Cancer, 43, 258 270.
6. Brewster, U.C. (2006) Intravenous iron therapy in end-stage renal disease. Seminars in Dialysis, 19, 285 290.
7. Canadian erythropoietin study group (1990) Association between recombinant human erythropoietin and quality of life and exercise capacity of patients receiving haemodialysis. British Medical Journal, 300, 573 578.
8. Cavill, I., Auerbach, M., Bailie, G.R., Barrett-Lee, P., Beguin, Y., Kaltwasser, P., Littlewood, T., Macdougall, I.C. Wilson, K. (2006) Iron and the anaemia of chronic disease: a review and strategic recommendations. Current Medical Research and Opinion, 22, 731 737.
9. Chang, J., Couture, F., Young, S., McWatters, K.L. Lau, C.Y. (2005) Weekly epoetin Alfa maintains hemoglobin, improves quality of life, and reduces transfusion in breast Cancer patients receiving chemotherapy. Journal of Clinical Oncology, 23, 2597 2605.
10. Chertow, G.M., Mason, P.D., Vaage-Nilsen, O. Ahlmen, J. (2006) Update on adverse events associated with parenteral iron. Nephrology Dialysis and Transplantation, 21, 378 382.
11. Drueke, T.B., Locatelli, F., Clyne, N., Eckardt, K.U., Macdougall, I.C., Tsakiris, D., Burger, H.U. Scherhag, A. (2006) Normalisation of hemoglobin levels in patients with chronic kidney disease and anemia. New England Journal of Medicine, 355, 2071 2084.
12. Fielding, J. (1977) Does sarcoma occur in man after intramuscular iron? Scandinavian Journal of Haematology. Supplement, 32, 100 104.
13. Fishbane, S., Mittal, S.K. Maesaka, J.K. (1999) Beneficial effects of iron therapy in renal failure patients on hemodialysis. Kidney International Supplement, 55, S67 S70.
14. Frankenfield, D.L., Neu, A.M., Warady, B.A., Fivush, B.A., Johnson, C.A. Brem, A.S. (2003) Anemia in pediatric hemodialysis patients: results from the 2001 ESRD clinical performance measures project. Kidney International, 64, 1120 1124.
15. Ganz, T. (2006) Hepcidin and its Role in Regulating Systemic Iron Metabolism. Hematology - American Society of Hematology Education Program, 29 35.
16. Hamstra, R.D., Block, M.H. Schocket, A.L. (1980) Intravenous iron dextran in clinical medicine. Journal of the American Medical Association, 243, 1726 1731.
17. Hedenus, M., Adriansson, M., San Miguel, J., Kramer, M.H.H., Schipperus, M.R., Juvonen, E., Taylor, K., Belch, A., Altés, A., Martinelli, G., Watson, D., Matcham, J., Rossi, G. Littlewood, T.J. (2003) Efficacy and safety of darbepoetin alfa in anaemic patients with lymphoproliferative malignancies; a randomised, double-blind, placebo controlled study. British Journal of Haematology, 122, 394 403.
18. Hedenus, M., Birgegard, G., Nasman, P., Ahlberg, L., Karlsson, T., Lauri, B., Lundin, J., Larfars, G. Osterborg, A. (2007) Addition of intravenous iron to epoetin beta increases haemoglobin response and decreases epoetin dose requirement in anemic patients with lymphoproliferative malignancies: a randomised multicenter study. Leukemia, 21, 627 632.
19. Henke, M., Laszig, R., Rube, C., Schafer, U., Haase, K.D., Schilcher, B., Mose, S., Beer, K.T., Burger, U., Dougherty, C. Frommhold, H. (2003) Erythropoietin to treat head and neck cancer patients with anaemia undergoing radiotherapy: randomised, double-blind, placebo-controlled trial. Lancet, 362, 1255 1260.
20. Henry, D.H., Dahl, N.V., Auerbach, M., Tchekmedyian, S. Laufman, L.R. (2007) Intravenous ferric gluconate significantly improves response to epoetin alfa versus oral iron or no iron in anemic patients with cancer receiving chemotherapy. The Oncologist, 12, 231 242.
21. Hershko, C., Peto, T.E.A. Weatherall, D.J. (1988) Iron and infection. British Medical Journal, 296, 660 664.
22. Kim, Y.T., Kim, S.W., Yoon, B.S., Cho, H.J., Nahm, E.J., Kim, S.H., Kim, J.H. Kim, J.W. (2007) Effect of intravenously administered iron sucrose on the prevention of anemia in the cervical cancer patients treated with concurrent chemoradiotherapy. Gynecologic Oncology, 105, 199 204.
23. Lerchenmueller, C., Husseini, F., Gaede, B., Mossman, T., Suto, T. Vandebroek, A. (2006). Intravenous (IV) iron supplementation in patients with chemotherapy-induced anemia (CIA) receiving darbepoetin alfa every 3 weeks (Q3W): iron parameters in a randomized controlled trial. Blood 108 Abstract 1552.
24. Lin, L., Valore, E.V., Nemeth, E., Goodnough, J.B., Gabayan, V. Ganz, T. (2007) Iron transferrin regulates hepcidin synthesis in primary hepatocyte culture through hemojuvelin and BMP2/4. Blood, 110, 2182 2189.
25. Littlewood, T.J., Bajetta, E., Nortier, J.W., Vercammen, E. Rapoport, B. (2001) Effects of epoetin alfa on hematologic parameters and quality of life in cancer patients receiving nonplatinum chemotherapy: results of a randomized, double-blind, placebo-controlled trial. Journal of Clinical Oncology, 19, 2865 2874.
26. Locatelli, F. (2004) Revised European Best Practice Gudelines for the management of anaemia in patients with chronic renal failure. Nephrology Dialysis Transplantation, 19 (Suppl. 2 ii1 ii47.
27. Ludwig, H., Van Belle, S., Barrett-Lee, P., Birgegard, G., Bokemeyer, C., Gascon, P., Kosmidis, P., Krzakowski, M., Nortier, J., Olmi, P., Schneider, M. Schrijvers, D. (2004) The European cancer anaemia survey (ECAS): a large, multi-national, prospective survey defining the prevalence, incidence and treatment of anaemia in cancer patients. European Journal of Cancer, 40, 2293 2306.
28. Means, R.T. (1995) Pathogenesis of the anemia of chronic disease: a cytokine-mediated anemia. Stem Cells, 13, 32 37.
29. Oppenheimer, S.J. (2001) Iron and its relation to immunity and infectious disease. Journal of Nutrition, 131, 616S 635S.
30. Pinter, T., Mossman, T., Suto, T. Vansteenkiste, J. (2007) Effects of intravenous (IV) iron supplementation on responses to every- 3-week (q3w) darbepoetin alfa (DA) by baseline haemoglobin in patients (pts) with chemotherapy-induced anemia (CIA). Proceedings of the American Society of Clinical Oncology, 25, 9106.
31. Reveiz, L., Gyte, G.M. Cuervo, L.G. (2001). Treatments for iron deficiency anaemia in pregnancy. Cochrane Database Systemic Reviews 18 CD003094.
32. Silverstein, S.B. Rodgers, G.M. (2004) Parenteral iron therapy options. American Journal of Hematology, 76, 74 78.
33. Singh, A.K., Szczech, L., Tang, K.L., Barnhart, H., Sapp, S., Wolfson, M. Reddan, D. (2006a) Correction of anemia with epoetin alfa in chronic kidney disease. New England Journal of Medicine, 355, 2085 2098.
34. Singh, H., Reed, J., Noble, S., Cangiano, J.L. Van Wyck, D.B. (2006b) Effect of intravenous iron sucrose in peritoneal dialysis patients who receive erythropoiesis-stimulating agents for anemia: a randomized, controlled trial. Clinical Journal of the American Society of Nephrology, 1, 475 482.
35. Vandebroek, A., Altintas, S., Gaede, B., Smith, K., Yao, B. Schupp, M. (2006) Darbepoetin alfa administered every 3 weeks with or without parenteral iron in anaemic patients with non-myeloid malignancies receiving chemotherapy: interim results from a randomized, open-label study. Haematologica, 91 (Suppl. 1 abstract 0029.
36. Weiss, G. Goodnough, L.T. (2005) Anemia of chronic disease. New England Journal of Medicine, 352, 1011 1023.
37. Winearls, C., Oliver, D.O., Pippard, M.J., Reid, C., Downing, M.R. Cotes, P.M. (1986) Effect of human erythropoietin derived from recombinant DNA on the anaemia of patients maintained by chronic haemodialysis. Lancet, 2, 1175 1178.
38. Witzig, T.E., Silberstein, P.T., Loprinzi, C.L., Sloan, J.A., Novotny, P.J., Mailliard, J.A., Rowland, K.M., Alberts, S.R., Krook, J.E., Levitt, R. Morton, R.F. (2005) Phase III, randomised, double blind study of epoetin alfa compared with placebo in anaemic patients receiving chemotherapy. Journal of Clinical Oncology, 23, 2606 2617.
39. Wright, J.R., Ung, Y.C., Julian, J.A., Pritchard, K.I., Whelan, T.J., Smith, C., Szechtman, B., Roa, W., Mulroy, L., Rudinskas, L., Gagnon, B., Okawara, G.S. Levine, M.N. (2007) Randomised, double-blind, placebo-controlled trial of erythropoietin in non-small-cell lung cancer with disease-related anemia. Journal of Clinical Oncology, 25, 1027 1032.